News from shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

23 Feb, 2015, 06:00 GMT Shire Calls for Improved Rare Disease Diagnosis on Rare Disease Day 2015

New awareness materials posted on Shire.com highlight the challenging diagnosis journey many people with a rare disease face Average time to...


21 Feb, 2015, 15:26 GMT Shire Completes Acquisition of NPS Pharma

Shire plc (LSE: SHP, NASDAQ: SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals,...


30 Jan, 2015, 23:24 GMT Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) approved Vyvanse® (lisdexamfetamine dimesylate)...


27 Jan, 2015, 22:00 GMT U.S. Supreme Court Grants Shire Petition

- LIALDA Patent Case Sent Back to Federal Circuit Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Supreme Court granted Shire's...


26 Jan, 2015, 07:00 GMT Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP609...


24 Jan, 2015, 01:34 GMT Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)

Shire plc (LSE: SHP, NASDAQ: SHPG) notes the announcement today by NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) that the U.S. Food and Drug...


22 Jan, 2015, 07:02 GMT Positive Response from European Decentralised Procedure for Elvanse Adult®▼ (lisdexamfetamine dimesylate) in Adults with ADHD

For Release to Pan-European Media Only Shire plc (LSE: SHP, NASDAQ: SHPG) today announces the positive response from the European Decentralised...


21 Jan, 2015, 21:34 GMT Shire Added to Global 100 Sustainability Index

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has for the first time placed in the Global 100 Sustainability Index. Shire was ranked 62nd in...


06 Jan, 2015, 14:00 GMT Shire to Present at 33rd Annual J.P. Morgan Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that Flemming Ornskov, MD, Chief Executive Officer, will present at the 33rd Annual J.P. Morgan...


10 Dec, 2014, 12:00 GMT Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020

Shire plc (LSE: SHP, NASDAQ: SHPG) is hosting a Research and Development (R&D) Day for the investment community focused on the Company's pipeline of...


01 Dec, 2014, 12:30 GMT Shire to Highlight Pipeline Progress and Breadth of Innovative Portfolio in R&D Day

Company to Profile Key Late-Stage Assets Projected to Drive $3 Billion in Growth by 2020 Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it...


19 Nov, 2014, 14:25 GMT Shire to Relocate Over 500 Jobs to Massachusetts

Establishes Lexington, Mass., as U.S. Operational Headquarters; Decreases Presence in Chesterbrook, Pa. Interim CFO Appointed Shire plc (LSE: SHP,...


06 Nov, 2014, 12:00 GMT Shire to Participate at the Credit Suisse 2014 Global Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it will be participating in the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, ...


24 Oct, 2014, 12:00 BST Shire's Clear and Focused Strategy Delivers Record Quarterly Revenues. Non GAAP Diluted Earnings per ADS up 60%

- Increases Non GAAP diluted earnings per ADS growth guidance to the high thirty percent range for the full year (2014). Shire (LSE: SHP, NASDAQ:...


20 Oct, 2014, 22:22 BST Shire plc: AbbVie Terminates Offer for Shire

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...


20 Oct, 2014, 07:00 BST Interim Chief Financial Officer James Bowling to Step Down

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling, Interim Chief Financial Officer (CFO), has notified the Board of Directors of his...


16 Oct, 2014, 09:32 BST Shire plc: Statement re: AbbVie's Withdrawal of Recommendation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...


15 Oct, 2014, 19:32 BST Shire plc: Statement re: Waiver of Notice of AbbVie's Board Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...


15 Oct, 2014, 07:13 BST Shire plc: Statement re: AbbVie's Intention to Reconsider Recommendation

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...


09 Oct, 2014, 09:30 BST Shire Provides Regulatory Update on SHP 465, Investigational Compound for ADHD in Adults

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has received further guidance from the U.S. Food and Drug Administration (FDA) on the...


24 Sep, 2014, 21:06 BST Shire Reaches Final Agreement with U.S. Government

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached a final agreement with the U.S. Attorney's Offices for the Eastern District...


15 Sep, 2014, 13:00 BST Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder

Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA)...


23 Jul, 2014, 12:00 BST Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen

- Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community Shire plc (LSE: SHP, NASDAQ: SHPG),...


18 Jul, 2014, 11:14 BST Shire Delivers Record Quarterly Revenues and Non GAAP Diluted Earnings per ADS up 42%

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF...


17 Jul, 2014, 18:30 BST Shire Reports Top-Line Results From Two Head-to-Head Studies Comparing Vyvanse® (lisdexamfetamine dimesylate), CII, With Concerta® (methylphenidate HCl), CII, in Adolescents with ADHD

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse® (lisdexamfetamine...